Compare WHR & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHR | URGN |
|---|---|---|
| Founded | 1911 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 1994 | 2016 |
| Metric | WHR | URGN |
|---|---|---|
| Price | $37.76 | $41.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $74.33 | $29.29 |
| AVG Volume (30 Days) | ★ 2.3M | 681.9K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | ★ 196.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,253,000,000.00 | $1,128,000.00 |
| Revenue This Year | N/A | $129.09 |
| Revenue Next Year | $3.48 | $70.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.58 | N/A |
| 52 Week Low | $35.45 | $15.86 |
| 52 Week High | $96.46 | $43.93 |
| Indicator | WHR | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 49.45 | 58.93 |
| Support Level | $36.04 | $18.23 |
| Resistance Level | $45.07 | $43.93 |
| Average True Range (ATR) | 1.88 | 2.04 |
| MACD | 0.21 | -0.34 |
| Stochastic Oscillator | 46.82 | 51.12 |
Whirlpool Corp is a manufacturer and marketer of kitchen and laundry appliances, with its presence in different markets around the world. It offers products like refrigerators, washing machines, cooktops, ovens, freezers, and others, which are marketed through various brands such as KitchenAid, Maytag, Amana, Brastemp, Consul, Whirlpool, Jennair, etc. The company's operating and reportable segments are: Major Domestic Appliances (MDA) North America (its key revenue-generating segment), MDA Europe, MDA Latin America, and Small Domestic Appliances (SDA) Global.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.